Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 26, 2023; 11(3): 566-575
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.566
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.566
Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
Yao-Wei Wang, Xin-Hui Wang, Hong-Xia Wang, Ren-Huan Yu, China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Author contributions: Wang HX and Wang YW contributed to the conception and design of the study; Wang HX, Wang YW, and Wang XH contributed to data collection, analysis, and interpretation; Wang YW and Wang XH wrote the manuscript; Yu RH critically revised the manuscript for important intellectual content; All authors revised the manuscript and approved the submitted version.
Supported by National Key Research and Development Program of China , No. 2019YFC1708503 .
Institutional review board statement: The study protocol was approved by the ethics review board of Xiyuan Hospital, China’s Academy of Chinese Medical Sciences (Beijing, China, approved No. 2022XLA130-2). All of the procedures were performed in accordance with the Declaration of Helsinki and relevant policies in China.
Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ren-Huan Yu, PhD, Professor, China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. tezhongeyu@vip.sina.com
Received: September 6, 2022
Peer-review started: September 6, 2022
First decision: October 11, 2022
Revised: October 14, 2022
Accepted: December 15, 2022
Article in press: December 15, 2022
Published online: January 26, 2023
Peer-review started: September 6, 2022
First decision: October 11, 2022
Revised: October 14, 2022
Accepted: December 15, 2022
Article in press: December 15, 2022
Published online: January 26, 2023
Core Tip
Core Tip: According to the Kidney Disease Improving Global Outcomes 2021 guidelines, Rituximab (RTX) is now the first-line therapy for patients with idiopathic membranous nephropathy (IMN). However, the use of RTX for the treatment of patients with refractory IMN remains challenging. We conducted a retrospective study on nine patients with refractory IMN to explore the efficacy and safety of a new low-dose RTX regimen (RTX, 200 mg, once a month for five months), and conclude that our low-dose RTX regimen is a promising treatment strategy for refractory IMN.